Repros Therapeutics Inc. RPRX is expected to report third-quarter 2017 results around Nov 14. Let’s see how things are shaping up for this quarter.
Repros Therapeutics’ share price has plunged 62.2% year to date, while the industry has gained 3.9%.
With no approved products in its portfolio yet, investors are expected to remain focused on Repros’ pipeline-related updates. The company’s pipeline presently comprises enclomiphene and Proellex.
The company’s most advanced pipeline candidate, enclomiphene, is currently under review in the EU and the United States. Repros is developing the candidate for the treatment of secondary hypogonadism. As part of the review process, the company has filed its responses to questions from EMA in this quarter.
Proellex is currently in phase II studies, which are evaluating the oral administration of the candidate in patients with endometriosis and uterine fibroids. The FDA placed the studies under clinical hold in 2009. But later, the FDA allowed the studies to continue under a partial clinical hold with low oral dosage. In July, the company announced that the study will continue to remain under partial clinical hold.
Moreover, the FDA has instructed the company to accumulate a large pre-approval safety database for the candidate to be evaluated further. To meet the FDA’s requirement, the company is supposed to conduct a much bigger clinical study, which we expect will be time consuming as well as expensive.
The company is also evaluating Proellex in a phase IIb study for uterine fibroids by vaginal delivery. However, this study has no clinical hold issues and last November, the company presented positive top-line data from the same.
In the first two quarters of 2017, Repros reported a significant decrease in clinical development expenses for its pipeline candidate, which is expected to continue this quarter.
Repros Therapeutics Inc. Price and EPS Surprise
Repros Therapeutics Inc. Price and EPS Surprise | Repros Therapeutics Inc. Quote
Stocks That Warrant a Look
Per our model, here are some health care stocks worth considering, as all have the right combination of elements – a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) – to come up with an earnings beat this quarter:
Agenus Inc. AGEN is scheduled to release results on Nov 7. It has an Earnings ESP of +8.11% and carries a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Cidara Therapeutics, Inc. CDTX is scheduled to release results on Nov 8. The company has an Earnings ESP of +16.06% and holds a Zacks Rank #2.
Regenxbio Inc. RGNX is scheduled to release results on Nov 8. The company has an Earnings ESP of +4.23% and carries a Zacks Rank #2.
You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Wall Street’s Next Amazon
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Click for details >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Agenus Inc. (AGEN) : Free Stock Analysis Report
Cidara Therapeutics, Inc. (CDTX) : Free Stock Analysis Report
REGENXBIO Inc. (RGNX) : Free Stock Analysis Report
To read this article on Zacks.com click here.